New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
06:08 EDTADHDBioBlast said to be preparing $37.5M Nasdaq IPO, Globes reports
BioBlast Pharma, an Israeli drug development company, is preparing a $37.5M Nasdaq IPO, sources tell Globes. BioBlast founders Dr. Dalia Megiddo and Udi Gilboa took Alcobra Pharmaceuticals public in 2013, raising $25M last May and another $38M in a secondary offering in October. Reference Link
News For ADHD From The Last 14 Days
Check below for free stories on ADHD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 15, 2014
10:28 EDTADHDHigh option volume stocks
High option volume stocks: TRGT ALB UUP ADHD ROC WWW CTRL KERX IMGN NI
July 14, 2014
17:29 EDTADHDAlcobra files to sell $100M of ordinary shares
Subscribe for More Information
09:15 EDTADHDAlcobra management to meet with Maxim
Subscribe for More Information
08:11 EDTADHDAlcobra completes patient recruitment in Phase III clinical trial of MDX
Alcobra announced that recruitment of patients has been completed in the company's Phase III clinical trial of Metadoxine Extended Release, or MDX, in adult ADHD patients. The study is a 300-patient, randomized, placebo-controlled trial conducted at 18 sites in the United States and 2 in Israel. Patients were randomized to receive either 1400 mg MDX or placebo over 6 weeks following a 2-week screening period. The primary endpoint is the Conners' Adult ADHD Rating Scale, or CAARS-INV, a widely accepted clinical measure of the presence and severity of ADHD symptoms. Secondary endpoints include the computerized TOVA, or Test of Variables of Attention, which was also used in the previous Phase 2 studies, as well as safety assessments and additional exploratory endpoints.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use